RESUMO
The large-scale and cost-effective production of quality-controlled human pluripotent stem cells (hPSCs) for use in cell therapy and drug discovery would ideally require a chemically defined xenobiotic-free culture system. Towards the development of such a system, costs associated with the use of recombinant proteins as supplements in basal culture media need to be reduced. Here, we describe a growth-factor-free culture medium that uses just three chemical compounds and a lower number of recombinant proteins than used in commercially available media. We show that the culture medium supports the long-term propagation of hPSCs, as confirmed by karyotype, the expression of pluripotency markers and the capacity to differentiate into cell types derived from the three embryonic germ layers. hPSCs growing in the medium were less dependent on glycolytic pathways than cells grown in medium containing growth factors. Moreover, the medium supported the generation of induced pluripotent stem cells derived from either human dermal fibroblasts or peripheral blood mononuclear cells. Our findings should facilitate the ongoing development of a completely xeno-free, chemically defined, synthetic culture system for hPSCs.
Assuntos
Técnicas de Cultura de Células/métodos , Células-Tronco Pluripotentes , Diferenciação Celular , Células Cultivadas , Meios de Cultura/química , Meios de Cultura/metabolismo , Fibroblastos/citologia , Fibroblastos/fisiologia , Humanos , Peptídeos e Proteínas de Sinalização Intercelular , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/fisiologia , Células-Tronco Pluripotentes/citologia , Células-Tronco Pluripotentes/fisiologiaRESUMO
Therapeutic effects of HL for a collagen-induced arthritis (CIA) mouse models of HL-23 composed of 95mol% l-α-dimyristoylphosphatidylcholine (DMPC) and 5mol% polyoxyethylenedodecylether (C12(EO)23) in vivo were examined. Remarkably high therapeutic effects of HL-23 for CIA mouse models were obtained on the basis of clinical assessment of arthritis. The reduction of hyperplastic synovial membrane (pannus tissue) and destruction of the cartilage and bone by HL-23 was revealed on the basis of hematoxylin and eosin (HE) and safranin O staining. Furthermore, the downregulation of inflammatory cytokines such as interleukin (IL)-1ß, tumor necrosis factor (TNF)-α, and IL-6 for CIA mouse models treated with HL-23 were investigated. Remarkably high therapeutic effects without joint swelling were obtained in CIA mouse models treated with HL-23.
Assuntos
Artrite Experimental/tratamento farmacológico , Artrite Experimental/imunologia , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/imunologia , Citocinas/metabolismo , Mediadores da Inflamação/metabolismo , Lipossomos/química , Lipossomos/uso terapêutico , Animais , Artrite Experimental/patologia , Artrite Reumatoide/patologia , Dimiristoilfosfatidilcolina/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Feminino , Humanos , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Camundongos , Camundongos Endogâmicos DBA , Polietilenoglicóis/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Hybrid liposomes (HLs) can be prepared by simply sonicating a mixture of vesicular and micellar molecules in buffer solutions. This study aims to demonstrate inhibitory effects of HLs on the growth of fibroblast-like synoviocytes along with apoptosis and therapeutic effects of HLs in a mouse model with rheumatoid arthritis (RA). HLs composed of 95 mol% L-α-dimyristoylphosphatidylcholine (DMPC) and 5 mol% polyoxyethylene(23)dodecyl ether (C12(EO)23) were prepared by the sonication method. The inhibitory effects of HLs on the growth of human fibroblast-like synoviocytes-RA (HFLS-RA) cells in vitro and their inhibitory mechanism were examined. High inhibitory effects of HLs on the growth of HFLS-RA cells were observed. The induction of apoptosis by HLs was revealed on the basis of flow cytometric analysis. Furthermore, therapeutic effects of HLs in the mouse model with RA were examined in vivo. Our results demonstrate that HLs showed inhibitory effects on the growth of HFLS-RA cells in vitro along with apoptosis and therapeutic effects in mouse models of RA in vivo.
Assuntos
Apoptose/efeitos dos fármacos , Artrite Experimental , Artrite Reumatoide , Proliferação de Células/efeitos dos fármacos , Dimiristoilfosfatidilcolina/farmacologia , Fibroblastos/efeitos dos fármacos , Lipossomos/farmacologia , Polietilenoglicóis/farmacologia , Membrana Sinovial/efeitos dos fármacos , Animais , Linhagem Celular , Modelos Animais de Doenças , Humanos , Técnicas In Vitro , Camundongos , Membrana Sinovial/citologiaRESUMO
Therapeutic effects of cationic hybrid liposomes (HL) composed of 87 mol% dimyristoyl-phosphatidylcholine (DMPC), 5 mol% polyoxyethylene (21) dodecyl ether (C12(EO)21) and 8 mol% O,O'-ditetradecanoyl-N-(α-trimethyl-ammonioacetyl) diethanolamine chloride (2C14ECl) on the metastasis of human colon carcinoma (HCT116) cells were examined in vivo. Cationic HL having a hydrodynamic diameter less than 150 nm were preserved for one month. Therapeutic effects were obtained in the hepatic metastasis mouse models of HCT116 cells after the intravenous injection of cationic HL. The histological analysis indicated the induction of apoptosis in the liver section of the hepatic metastasis mouse models treated with cationic HL in vivo. Therapeutic effects of cationic HL without any drugs on the hepatic metastasis were revealed for the first time on the basis of histological analyses in vivo.
Assuntos
Antineoplásicos/uso terapêutico , Apoptose , Cátions/uso terapêutico , Neoplasias do Colo/patologia , Lipossomos/uso terapêutico , Neoplasias Hepáticas/tratamento farmacológico , Fígado/efeitos dos fármacos , Animais , Antineoplásicos/química , Dimiristoilfosfatidilcolina/química , Etanolaminas/química , Células HCT116 , Humanos , Lipossomos/química , Fígado/patologia , Neoplasias Hepáticas/secundário , Camundongos , Camundongos Endogâmicos BALB C , Polietilenoglicóis/químicaRESUMO
New-type three-component cationic hybrid liposomes (HLs) composed of dimyristoylphosphatidylcholine (DMPC), polyoxyethylene(21)dodecyl ether (C(12)(EO)(21)) and O,O'-ditetradecanoyl-N-(α-trimethylammonioacetyl) diethanolamine chloride (2C(14)ECl) were produced. Cationic HLs were smaller and more stable than pure DMPC liposomes. It is noteworthy that cationic HLs could remarkably inhibit the growth of human colon cancer (HCT116) cells along with apoptosis in vitro for the first time in this study.
Assuntos
Antineoplásicos/administração & dosagem , Dimiristoilfosfatidilcolina/administração & dosagem , Etanolaminas/administração & dosagem , Miristatos/administração & dosagem , Polietilenoglicóis/administração & dosagem , Apoptose/efeitos dos fármacos , Carcinoma , Proliferação de Células/efeitos dos fármacos , Neoplasias do Colo , Dimiristoilfosfatidilcolina/química , Etanolaminas/química , Células HCT116 , Humanos , Lipossomos , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Miristatos/química , Polietilenoglicóis/químicaRESUMO
Therapeutic effects of hybrid liposomes (HL) composed of l-α-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene(25) dodecyl ether (C(12)(EO)(25)) on the metastasis of human colon carcinoma (HCT116) cells were examined in vivo. Remarkably high therapeutic effects were obtained in the xenograft mouse models of colorectal cancer (CRC) liver metastases after treatment with HL-25 on the basis of relative liver weight and histological analysis of the liver tissue sections of mouse models with HE staining, and TUNEL staining for detection of apoptotic cells. The survival effects of HL-25 were obtained using xenograft mouse models of CRC liver metastases. Furthermore, with regard to pharmacokinetics, the accumulation of fluorescent labeled HL-25 was observed in the liver tissue of xenograft mouse models of CRC liver metastases for 24 h after the intravenous injection of fluorescent labeled HL-25. Therapeutic effects of HL without any drugs on the liver metastasis of human CRC were revealed for the first time in vivo.
Assuntos
Antineoplásicos/farmacologia , Carcinoma/tratamento farmacológico , Neoplasias Colorretais/tratamento farmacológico , Dimiristoilfosfatidilcolina/farmacologia , Lipossomos/farmacologia , Neoplasias Hepáticas/tratamento farmacológico , Polietilenoglicóis/farmacologia , Animais , Antineoplásicos/química , Apoptose/efeitos dos fármacos , Carcinoma/mortalidade , Carcinoma/secundário , Neoplasias Colorretais/mortalidade , Neoplasias Colorretais/patologia , Dimiristoilfosfatidilcolina/química , Feminino , Corantes Fluorescentes , Humanos , Marcação In Situ das Extremidades Cortadas , Injeções Intravenosas , Lipossomos/química , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/secundário , Camundongos , Camundongos SCID , Tamanho do Órgão/efeitos dos fármacos , Polietilenoglicóis/química , Taxa de Sobrevida , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Inhibitory effects of HL-n composed of 95 mol% L-α-dimyristoylphosphatidylcholin (DMPC) and 5 mol% polyoxyethylenedodecylether (C(12)(EO)(n), n = 21, 23, or 25) on the growth of human rheumatoid arthritis (RA) fibroblast-like synoviocytes (HFLS-RA) in vitro were examined. Remarkably high inhibitory effects of HL-n on the growth of HFLS-RA cells were obtained. The induction of apoptosis by HL-n was revealed on the basis of TUNEL method. Furthermore, the therapeutic effects of HL-23 using mouse models of arthritis were investigated. Therapeutic effects without joint swelling were obtained in mouse models of RA treated with HL.